Ikuto Tsukiyama1,2, Masahiko Ando3, Sumiyo Tsukiyama2, Masayuki Takeuchi2, Masayuki Ejiri2, Yusuke Kurose2, Hiroko Saito2, Ichiro Arakawa4, Tadao Inoue5, Etsuro Yamaguchi6, Akihito Kubo7. 1. Faculty of Pharmacy, Meijo University, Nagoya, Japan. 2. Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Japan. 3. Center for Advanced Medical and Clinical Research, Nagoya University Hospital, Nagoya, Japan. 4. Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan. 5. School of Pharmaceutical Sciences, Ohu University, Koriyama, Japan. 6. Division of Respiratory Medicine and Allergology, School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan. 7. Division of Respiratory Medicine and Allergology, School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan. kuboa@aichi-med-u.ac.jp.
Abstract
PURPOSE: Neurokinin-1 receptor antagonist (NK1RA) is recommended to prevent chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly or moderately emetogenic chemotherapy (HEC or MEC, respectively). We previously reported that aprepitant, an NK1RA, was needed to control CINV in 43% and 12% of patients who received HEC and MEC, respectively (Support Care Cancer 23:905-912, 2015). To elucidate the cost-effectiveness of aprepitant in these patients, a cost-utility analysis according to the necessity of aprepitant was performed. METHODS: A decision-analytic model was developed according to the necessity of aprepitant and CINV responses in both acute and delayed phases of chemotherapy. Probabilities of health states and medical costs were derived from the results of the abovementioned trial. RESULT: In patients who received HEC and needed aprepitant, the incremental cost-effectiveness ratio (ICER) with aprepitant, relative to the regimen with no aprepitant, was 7912 US dollars (USD) per quality-adjusted life year (QALY) gained, which was far below the commonly accepted threshold of 50,000 USD/QALY. The ICER was 27,457 USD/QALY in patients who received MEC and needed aprepitant. In contrast, in patients who received HEC or MEC but did not need aprepitant, the ICER was 175,959 or 478,844 USD/QALY, respectively. CONCLUSION: Regardless of whether a patient received HEC or MEC, aprepitant use was highly cost-effective for patients who truly needed it. These results warrant further research to predict the necessity of NK1RA treatment before initiating emetogenic chemotherapies.
PURPOSE: Neurokinin-1 receptor antagonist (NK1RA) is recommended to prevent chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly or moderately emetogenic chemotherapy (HEC or MEC, respectively). We previously reported that aprepitant, an NK1RA, was needed to control CINV in 43% and 12% of patients who received HEC and MEC, respectively (Support Care Cancer 23:905-912, 2015). To elucidate the cost-effectiveness of aprepitant in these patients, a cost-utility analysis according to the necessity of aprepitant was performed. METHODS: A decision-analytic model was developed according to the necessity of aprepitant and CINV responses in both acute and delayed phases of chemotherapy. Probabilities of health states and medical costs were derived from the results of the abovementioned trial. RESULT: In patients who received HEC and needed aprepitant, the incremental cost-effectiveness ratio (ICER) with aprepitant, relative to the regimen with no aprepitant, was 7912 US dollars (USD) per quality-adjusted life year (QALY) gained, which was far below the commonly accepted threshold of 50,000 USD/QALY. The ICER was 27,457 USD/QALY in patients who received MEC and needed aprepitant. In contrast, in patients who received HEC or MEC but did not need aprepitant, the ICER was 175,959 or 478,844 USD/QALY, respectively. CONCLUSION: Regardless of whether a patient received HEC or MEC, aprepitant use was highly cost-effective for patients who truly needed it. These results warrant further research to predict the necessity of NK1RA treatment before initiating emetogenic chemotherapies.
Authors: Charlotte C Sun; Diane C Bodurka; Michele L Donato; Edward B Rubenstein; Candice L Borden; Karen Basen-Engquist; Mark F Munsell; John J Kavanagh; David M Gershenson Journal: Gynecol Oncol Date: 2002-10 Impact factor: 5.482
Authors: David G Warr; Paul J Hesketh; Richard J Gralla; Hyman B Muss; Jørn Herrstedt; Peter D Eisenberg; Harry Raftopoulos; Steven M Grunberg; Munir Gabriel; Anthony Rodgers; Norman Bohidar; George Klinger; Carolyn M Hustad; Kevin J Horgan; Franck Skobieranda Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D Carides; Guoguang Julie Ma; Krista Eldridge; Anita Hipple; Judith K Evans; Kevin J Horgan; Francesca Lawson Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Mats Bergström; Richard J Hargreaves; H Donald Burns; Michael R Goldberg; David Sciberras; Scott A Reines; Kevin J Petty; Mattias Ogren; Gunnar Antoni; Bengt Långström; Olli Eskola; Mika Scheinin; Olof Solin; Anup K Majumdar; Marvin L Constanzer; Wendy P Battisti; Thomas E Bradstreet; Cynthia Gargano; Jarmo Hietala Journal: Biol Psychiatry Date: 2004-05-15 Impact factor: 13.382
Authors: H J Schmoll; M S Aapro; S Poli-Bigelli; H-K Kim; K Park; K Jordan; J von Pawel; H Giezek; T Ahmed; C Y Chan Journal: Ann Oncol Date: 2006-03-08 Impact factor: 32.976